The Hyper-CVAD chemotherapy regimen has an adverse long-term impact on the ability to mobilize peripheral blood stem cells, which can be readily circumvented by using the early cycles for mobilization

Hematological Oncology

Volumn 24, Issue 3, 2006, Pages 159-163

  Keane, Colm ^a   Gibbs, Simon ^b   Seymour, John F ^b   Mills, Anthony K ^a   Grimmett, Karen ^a   Van Kuilenberg, Rosita ^a   Saal, Russell ^a   Gill, Devinder ^a   Prince, H Miles ^b   Marlton, Paula ^a   Mollee, Peter ^a  

^a PRINCESS ALEXANDRA HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Haematological malignancy; Hyper CVAD chemotherapy; Stem cell mobilization

Indexed keywords

CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; APHERESIS; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BURKITT LYMPHOMA; CANCER CHEMOTHERAPY; CONTROLLED STUDY; CYTOTOXICITY; DEMOGRAPHY; FEMALE; HUMAN; LYMPHOBLASTOMA; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; NEUTROPENIA; NONHODGKIN LYMPHOMA; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; SIDE EFFECT; STEM CELL MOBILIZATION;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD COMPONENT REMOVAL; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; GRAFT SURVIVAL; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; MALE; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS; VINCRISTINE;

EID: 33749243130     PISSN: 02780232     EISSN: 10991069     Source Type: Journal    
DOI: 10.1002/hon.784     Document Type: Article

References (34)

1. de la Rubia J, Arbona C, de Arriba F, et al. Analysis of factors associated with low peripheral blood progenitor cell collection in normal donors. Transfusion 2002; 42(1): 4-9.
2. D' Arena G, Musto P, Di Mauro L, et al. Predictive parameters for mobilized peripheral blood CD34 + progenitor cell collection in patients with hematological malignancies. Am J Hematol 1998; 58(4): 255-262.
3. Ketterer N, Salles G, Moullet I, et al. Factors associated with successful mobilization of peripheral blood progenitor cells in 200 patients with lymphoid malignancies. Br J Haematol 1998; 103(1): 235-242.
4. Haas R, Mohle R, Fruhauf S, et al. Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 1994; 83(12): 3787-3794.
5. Tarella C, Zallio F, Caracciolo D, et al. Hemopoietic progenitor cell mobilization and harvest following an intensive chemotherapy debulking in indolent lymphoma patients. Stem Cells 1999; 17(1): 55-61.
6. Bensinger W, Appelbaum F, Rowley S, et al. Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol 1995; 13(10): 2547-2555.
7. Drake M, Ranaghan L, Morris TC, et al. Analysis of the effect of prior therapy on progenitor cell yield: use of a chemotherapy scoring system. Br J Haematol 1997; 98(3): 745-749.
8. Bensinger WI, Longin K, Appelbaum F, et al. Peripheral blood stem cells (PBSCs) collected after recombinant granulocyte colony stimulating factor (rhG-CSF): an analysis of factors correlating with the tempo of engraftment after transplantation. Br J Haematol 1994; 87(4): 825-831.
9. Tricot G, Jagannath S, Vesole D, et al. Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. Blood 1995; 85(2): 588-596.
10. Moskowitz CH, Glassman JR, Wuest D, et al. Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphoma. Clin Cancer Res 1998; 4(2): 311-316.
11. Morgan SJ, Seymour JF, Grigg A, et al. Predictive factors for successful stem cell mobilization in patients with indolent lymphoproliferative disorders previously treated with fludarabine. Leukemia 2004; 18(5): 1034-1038.
12. Dreger P, Kloss M, Petersen B, et al. Autologous progenitor cell transplantation: prior exposure to stem cell-toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts. Blood 1995; 86(10): 3970-3978.
13. Weaver CH, Zhen B, Buckner CD. Treatment of patients with malignant lymphoma with Mini-BEAM reduces the yield of CD34 + peripheral blood stem cells. Bone Marrow Transplant 1998; 21(11): 1169-1170.
14. Kantarjian HM, O'Brien S, Smith TL, et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol 2000; 18(3): 547-561.
15. Kantarjian H, Thomas D, O'Brien S, et al. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer 2004; 101(12): 2788-2801.
16. Thomas DA, O'Brien S, Cortes J, et al. Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma. Blood 2004; 104(6): 1624-30.
17. Thomas DA, Cortes J, O'Brien S, et al. Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia. J Clin Oncol 1999; 17(8): 2461-2470.
18. Khouri IF, Romaguera J, Kantarjian H, et al. Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol 1998; 16(12): 3803-3809.
19. Shapiro M, Wasik MA, Junkins-Hopkins JM, et al. Complete remission in advanced blastic NK-cell lymphoma/leukemia in elderly patients using the hyper-CVAD regimen. Am J Hematol 2003; 74(1): 46-51.
20. Sutherland DR, Anderson L, Keeney M, Nayar R, Chin-Yee I. The ISHAGE guidelines for CD34 + cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering. J Hematother 1996; 5(3): 213-226.
21. Blystad AK, Delabie J, Kvaloy S, et al. Infused CD34 cell dose, but not tumour cell content of peripheral blood progenitor cell grafts, predicts clinical outcome in patients with diffuse large B-cell lymphoma and follicular lymphoma grade 3 treated with high-dose therapy. Br J Haematol 2004; 125(5): 605-612.
22. Jacquy C, Soree A, Lambert F, et al. A quantitative study of peripheral blood stem cell contamination in diffuse large-cell non-Hodgkin's lymphoma: one-half of patients significantly mobilize malignant cells. Br J Haematol 2000; 110(3): 631-637.
23. Demirkazik A, Kessinger A, Armitage JO, et al. Progenitor and lymphoma cells in blood stem cell harvests: impact on survival following transplantation. Bone Marrow Transplant 2001; 28(2): 207-212.
24. Vose JM, Sharp G, Chan WC, et al. Autologous transplantation for aggressive non-Hodgkin's lymphoma: results of a randomized trial evaluating graft source and minimal residual disease. J Clin Oncol 2002; 20(9): 2344-2352.
25. Kanteti R, Miller K, McCann J, et al. Randomized trial of peripheral blood progenitor cell vs bone marrow as hematopoietic support for high-dose chemotherapy in patients with non-Hodgkin's lymphoma and Hodgkin's disease: a clinical and molecular analysis. Bone Marrow Transplant 1999; 24(5): 473-481.
26. Nagafuji K, Harada M, Takamatsu Y, et al. Evaluation of leukaemic contamination in peripheral blood stem cell harvests by reverse transcriptase polytnerase chain reaction. Br J Haematol 1993; 85(3): 578-583.
27. Craig JI, Langlands K, Parker AC, Anthony RS. Molecular detection of tumor contamination in peripheral blood stem cell harvests. Exp Hematol 1994; 22(9): 898-902.
28. Balduzzi A, Gaipa G, Bonanomi S, et al. Purified autologous grafting in childhood acute lymphoblastic leukemia in second remission: evidence for long-term clinical and molecular remissions. Leukemia 2001; 15(1): 50-56.
29. Rambaldi A, Borleri G, Dotti G, et al. Innovative two-step negative selection of granulocyte colony-stimulating factor-mobilized circulating progenitor cells: adequacy for autologous and allogeneic transplantation. Blood 1998; 91(6): 2189-2196.
30. Carella AM, Frassoni F, Pollicardo N, et al. Philadelphia-chromosome- negative peripheral blood stem cells can be mobilized in the early phase of recovery after a myelosuppressive chemotherapy in Philadelphia-chromosome- positive acute lymphoblastic leukaemia. Br J Haematol 1995; 89(3): 535-538.
31. Rowe J. Autologous stem cell transplantation versus chemotherapy for acute lymphoblastic leukemia in first remission. In Autologous Blood and Marrow transplantation. Dicke KA, Keating A (eds). Carden Jennings Publishing Co Ltd: Charlottesville, 2001; 361-371.
32. Shimoni A, Korbling M. Tumor cell contamination in re-infused stem cell autografts: does it have clinical significance? Crit Rev Oncol Hematol 2002; 41(2): 241-250.
33. Clark RE, Brammer CG. Previous treatment predicts the efficiency of blood progenitor cell mobilization: validation of a chemotherapy scoring system. Bone Marrow Transplant 1998; 22(9): 859-863.
34. Mollee P, Pereira D, Nagy T, et al. Cyclophosphamide, etoposide and G-CSF to mobilize peripheral blood stem cells for autologous stem cell transplantation in patients with lymphoma. Bone Marrow Transplant 2002; 30(5): 273-278.